NCT05782270

Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy

Comparison of Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 202 (estimated)
• Sponsor: China National Center for Cardiovascular Diseases · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the final option for achieving complete revascularization in diffuse coronary artery disease patients. Since the exposure of subendothelial tissue to the blood flow after CE, the coagulation cascade can be activated, resulting in the increased risk of graft failure. Therefore, anticoagulation with warfarin in this group of patients might be beneficial. However, evidence is limited. This study aims to compare the clinical outcomes between dual antiplatelet therapy with or without warfarin after CE+CABG.

Conditions

• Anticoagulation
• Coronary Endarterectomy

Interventions

Type	Name	Description
DRUG	Warfarin	dual antiplatelet therapy combined with warfarin
DRUG	DAPT	Dual antiplatelet therapy (aspirin plus either clopidogrel or ticagrelor)
OTHER	CE+CABG	Coronary endarterectomy combined with coronary artery bypass grafting

Timeline

• Start date: 2023-04-11
• Primary completion: 2025-09-25
• Completion: 2026-05-30
• First posted: 2023-03-23
• Last updated: 2025-11-18

Locations

1 site across 1 country: China